Live feed09:15:00·21mPRReleasevia QuantisnowCreative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 PlanningByQuantisnow·Wall Street's wire, on your screen.CELZ· Creative Medical Technology Holdings Inc.Finance
